Akebia Therapeutics, Inc.AKBANASDAQ
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank100
3Y CAGR+81.1%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+81.1%/yr
Quarterly compound
Percentile
P100
Near historical high
vs 3Y Ago
5.9x
Strong expansion
Streak
3 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 82.20% |
| Q3 2025 | 32.81% |
| Q2 2025 | 12.91% |
| Q1 2025 | -17.24% |
| Q4 2024 | 38.87% |
| Q3 2024 | 10.98% |
| Q2 2024 | -21.42% |
| Q1 2024 | -1.36% |
| Q4 2023 | -25.99% |
| Q3 2023 | -34.00% |
| Q2 2023 | 2.60% |
| Q1 2023 | -38.30% |
| Q4 2022 | 13.83% |
| Q3 2022 | 7.69% |
| Q2 2022 | -40.62% |
| Q1 2022 | 48.30% |
| Q4 2021 | -26.97% |
| Q3 2021 | 8.75% |
| Q2 2021 | -8.36% |
| Q1 2021 | 8.07% |
| Q4 2020 | -19.80% |
| Q3 2020 | -11.29% |
| Q2 2020 | -34.98% |
| Q1 2020 | 1.02% |
| Q4 2019 | 7.92% |
| Q3 2019 | -13.05% |
| Q2 2019 | 4.06% |
| Q1 2019 | -5.47% |
| Q4 2018 | 23.33% |
| Q3 2018 | -1.78% |
| Q2 2018 | 17.12% |
| Q1 2018 | -10.20% |
| Q4 2017 | 16.47% |
| Q3 2017 | 34.19% |
| Q2 2017 | -27.14% |
| Q1 2017 | 79.60% |
| Q4 2016 | 7.03% |
| Q3 2016 | 1.17% |
| Q2 2016 | 52.59% |
| Q1 2016 | 61.38% |